Ana Vivancos

TL;DR: Analysis of cell-free plasma DNA collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD 9291 provides insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291.

TL;DR: It is shown that ctDNA derived from central nervous system tumours is more abundantly present in the cerebrospinal fluid (CSF) than in plasma, allowing the identification of actionable brain tumour somatic mutations and facilitating and complement the diagnosis of leptomeningeal carcinomatosis.

TL;DR: The Cancer Genome Interpreter is presented, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response.

TL;DR: It is shown that it is possible to evaluate the β-catenin status of patients' carcinomas and the response of patient-derived cells to target-directed drugs that accumulate FOXO3a in the nucleus before deciding on a course of treatment, and it is proposed that this evaluation could be essential to the provision of a safer and more effective personalized treatment.

TL;DR: The hypothesis that identification of a preexisting and stable adaptive immune response as defined by mRNA expression pattern is reproducible and sufficient to predict clinical outcome is supported, regardless of the type of cancer or the PD1 therapeutic antibody administered to patients.